Considerations when treating high-grade pediatric glioma patients with immunotherapy

Crotty, Erin; Downey, Kira; Ferrerosa, Lauren; Flores, Catherine; Hegde, Bindu; Raskin, Scott; Hwang, Eui-Hyoung; Vitanza, Nicholas A.; Okada, Hideho

doi:10.1080/14737175.2020.1855144

Cited by 7 publications

(6 citation statements)

References 163 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When we develop more potent strategies, although we did not observe any obvious toxicity in the current study, we should address close attention to possible CNS toxicities associated with peritumoral inflammation or CNS autoimmunity as we discussed recently. 20 Although Tc17-1 cells expressed CCR6 at higher levels than Tc1 cells, based on our data, CCR6 may not contribute significantly to antiglioma activity. EAE models demonstrated that Th17 cells cross the choroid plexus epithelial barrier in CCR6/CCL20-and LFA-1/ICAM-1-dependent manners, while Th1 cells cross the bloodbrain barrier using VLA-4.…”

Section: Open Accessmentioning

confidence: 59%

See 1 more Smart Citation

IFN-γ- and IL-17-producing CD8⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Ohkuri

Kosaka

Ikeura

et al. 2021

J Immunother Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundWhile adoptive transfer of T-cells has been a major medical breakthrough for patients with B cell malignancies, the development of safe and effective T-cell-based immunotherapy for central nervous system (CNS) tumors, such as glioblastoma (GBM), still needs to overcome multiple challenges, including effective homing and persistence of T-cells. Based on previous observations that interleukin (IL)-17-producing T-cells can traffic to the CNS in autoimmune conditions, we evaluated CD8+ T-cells that produce IL-17 and interferon-γ (IFN-γ) (Tc17-1) cells in a preclinical GBM model.MethodsWe differentiated Pmel-1 CD8+ T-cells into Tc17-1 cells and compared their phenotypic and functional characteristics with those of IFN-γ-producing CD8+ T (Tc1) and IL-17-producing CD8+ T (Tc17) cells. We also evaluated the therapeutic efficacy, persistence, and tumor-homing of Tc17-1 cells in comparison to Tc1 cells using a mouse GL261 glioma model.ResultsIn vitro, Tc17-1 cells demonstrated profiles of both Tc1 and Tc17 cells, including production of both IFN-γ and IL-17, although Tc17-1 cells demonstrated lesser degrees of antigen-specific cytotoxic activity compared with Tc1 cells. In mice-bearing intracranial GL261-Quad tumor and treated with temozolomide, Tc1 cells, but not Tc17-1, showed a significant prolongation of survival. However, when the T-cell transfer was combined with poly-ICLC and Pmel-1 peptide vaccine, both Tc1 and Tc17-1 cells exhibited significantly prolonged survival associated with upregulation of very late activation antigen−4 on Tc17-1 cells in vivo. Glioma cells that recurred following the therapy lost the susceptibility to Pmel-1-derived cytotoxic T-cells, indicating that immuno-editing was a mechanism of the acquired resistance.ConclusionsTc17-1 cells were equally effective as Tc1 cells when combined with poly-ICLC and peptide vaccine treatment.

show abstract

Section: Open Accessmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 99%

IFN-γ- and IL-17-producing CD8⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Ohkuri

Kosaka

Ikeura

et al. 2021

J Immunother Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…This toxicity can occur after immune checkpoint blockade treatment or adoptive T cell therapy with genetically engineered T cells ( 179 , 180 ). These toxicities need to be managed by carefully designing the immunotherapy agents and the clinical trials in both adult and pediatric patients ( 181 , 182 ).…”

Section: Treatmentmentioning

confidence: 99%

Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations

et al. 2022

View full text Add to dashboard Cite

High grade gliomas are identified as malignant central nervous tumors that spread rapidly and have a universally poor prognosis. Historically high grade gliomas in the pediatric population have been treated similarly to adult high grade gliomas. For the first time, the most recent classification of central nervous system tumors by World Health Organization has divided adult from pediatric type diffuse high grade gliomas, underscoring the biologic differences between these tumors in different age groups. The objective of our review is to compare high grade gliomas in the adult versus pediatric patient populations, highlighting similarities and differences in epidemiology, etiology, pathogenesis and therapeutic approaches. High grade gliomas in adults versus children have varying clinical presentations, molecular biology background, and response to chemotherapy, as well as unique molecular targets. However, increasing evidence show that they both respond to recently developed immunotherapies. This review summarizes the distinctions and commonalities between the two in disease pathogenesis and response to therapeutic interventions with a focus on immunotherapy.

show abstract

“…This rating scale looks at 3 different cell images and is classified each score from 1-3. The classifications are: Another benefit of determining the grading is to determine the response to therapy that will be given (Crotty et al, 2021). At a poor degree of differentiation, where cell growth and spread is considered to be more rapid or aggressive (Redmond, McCarthy, Buchanan, Levingstone, & Dunne, 2021), additional therapy is needed besides definitive, namely by administering chemoradiation.…”

Section: A Grade Breast Cancermentioning

confidence: 99%

The Analysis of Factors Affecting Stage Level of Breast Cancer Patients at RSUD DR. SOETOMO Surabaya

et al. 2022

View full text Add to dashboard Cite

Breast cancer is the cancer with the largest number in the world, and ranks as the fifth largest cause of death, which is 6.9% of the total 9,958,133 million cases of cancer deaths. Breast cancer is one of the main killers of women in the world and in Indonesia. Breast and cervical cancer dominate cancer cases in East Java. Throughout 2019, RSUD Dr. Soetomo Surabaya received 167,000 cancer patients, and the highest case was breast cancer. The high number of breast cancer sufferers makes this disease requires special attention. The cancer staging or staging system is based on whether the cancer has spread from the breast to other parts of the body. Cancer stage is divided into two categories, namely early stage (stages 0 to III A) and late stage (stages III B to IV). This study will examine the factors that affect the level of cancer stage in breast cancer patients at RSUD Dr. Soetomo Surabaya in 2019. Using the binary logistic regression analysis method, it was found that the factors that significantly influence the stage of breast cancer are Grade and Obesity with a classification correctness level of 82.5%.

show abstract

Considerations when treating high-grade pediatric glioma patients with immunotherapy

Cited by 7 publications

References 163 publications

IFN-γ- and IL-17-producing CD8⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

IFN-γ- and IL-17-producing CD8⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations

The Analysis of Factors Affecting Stage Level of Breast Cancer Patients at RSUD DR. SOETOMO Surabaya

Contact Info

Product

Resources

About

Considerations when treating high-grade pediatric glioma patients with immunotherapy

Cited by 7 publications

References 163 publications

IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations

The Analysis of Factors Affecting Stage Level of Breast Cancer Patients at RSUD DR. SOETOMO Surabaya

Contact Info

Product

Resources

About

IFN-γ- and IL-17-producing CD8⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

IFN-γ- and IL-17-producing CD8⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity